ASCENTAGE PHARMA GROUP INTERNATIONAL(AAPG)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 12 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
AAPG Stock Analysis & AI Quality Score
AI stock analysis and institutional research for ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG), a Healthcare sector company. AAPG is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 12 institutional filers currently hold this stock. Based on the latest XBRL financial filings (FY 2024), ASCENTAGE PHARMA GROUP INTERNATIONAL reports quarterly revenue of $134.3M, net income of $-55.6M. Top institutional holders of AAPG by reported 13-F value include Point72 Asset Management, L.P., XY Capital Ltd, Tower Research Capital (TRC), based on the most recent SEC filings. AAPG trades on the Nasdaq exchange and files with the SEC under CIK 2023311. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AAPG daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ASCENTAGE PHARMA GROUP INTERNATIONAL directly from SEC EDGAR.
Revenue
FY 2024
$134.3M
Net Income
FY 2024
$-55.6M
AI Insight: AAPG Financial Trends
Insufficient data: no quarterly financials available to identify trends or risks for Ascentage Pharma.
• No quarterly data provided; trend analysis cannot be performed.
⚠ Obtain quarterly financial statements before drawing any investment conclusions.
AI Insight: AAPG Ratio Trends
Insufficient ratio data available to draw meaningful financial trends for Ascentage Pharma Group International.
• No ratio data was provided; trend analysis cannot be performed.
⚠ Obtain revenue, margin, and cash flow data before forming any financial view.
Get alerted when AAPG's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ASCENTAGE PHARMA GROUP INTERNATIONAL including:
Top Institutional Holders of AAPG
Point72 Asset Management, L.P.
$383.3K16,056 shXY Capital Ltd
$310.6K13,014 shTower Research Capital LLC (TRC)
$12.4K518 shMORGAN STANLEY
$11.9K498 shUBS Group AG
$3.0K124 shEverSource Wealth Advisors, LLC
$2.5K71 shROYAL BANK OF CANADA
$0.006 sh
| Fund | Value | Shares |
|---|---|---|
| Point72 Asset Management, L.P. | $383.3K | 16,056 |
| XY Capital Ltd | $310.6K | 13,014 |
| Tower Research Capital LLC (TRC) | $12.4K | 518 |
| MORGAN STANLEY | $11.9K | 498 |
| UBS Group AG | $3.0K | 124 |
| EverSource Wealth Advisors, LLC | $2.5K | 71 |
| ROYAL BANK OF CANADA | $0.00 | 6 |
More Healthcare Companies
View all Healthcare →Put AAPG on your watchlist
Track score changes the day ASCENTAGE PHARMA GROUP INTERNATIONAL files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AAPG a good stock to buy?
13F Pro's AI-powered analysis of ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AAPG are available on the AAPG stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own AAPG?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AAPG. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ASCENTAGE PHARMA GROUP INTERNATIONAL's investment landscape.